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Abstract Glioblastoma multiforme (GBM) is the most
aggressive primary human brain tumor. The relatively high
amount of T regulatory lymphocytes present in the tumor,
contributes to the establishment of an immunosuppressive
microenvironment. Samples of peripheral blood were col-
lected from GBM patients and healthy controls and a
purified population of Treg (CD4?/CD25bright) was isolated
using flow cytometric cell sorting. Treg migrating capaci-
ties toward human glioma cell line conditioned medium
were evaluated through an in vitro migration test. Our data
show that supernatants collected from GBM cell lines were
more attractant to Treg when compared to complete stan-
dard medium. The addition of an anti-CCL2 antibody to
conditioned medium decreased conditioned medium-
depending Treg migration, suggesting that CCL2 (also
known as Monocyte Chemoattractant Protein, MCP-1) is
implicated in the process. The number of circulating
CD4?/lL or Treg/lL was similar in GBM patients and
controls. Specific Treg markers (FOXP3; CD127; Helios;
GITR; CTLA4; CD95; CCR2, CCR4; CCR7) were
screened in peripheral blood and no differences could be
detected between the two populations. These data confirm
that the tumor microenvironment is attractive to Treg,
which tend to migrate toward the tumor region changing
the immunological response. Though we provide evidence
that CCL2 is implicated in Treg migration, other factors are
needed as well to provide such effect.
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Introduction
Glioblastoma multiforme (GBM) is the most common and
aggressive cerebral tumor in adults in which treatment
options are very poor and recurrence occurs invariably
after surgical treatment and radio-chemotherapy [1, 2]. In
the last years, immunotherapy has been suggested as a
powerful approach to prevent tumor recurrence in a num-
ber of neoplasms by eliminating tumor cells while sparing
normal surrounding healthy cells [3].
T regulatory lymphocytes (Treg) are a subset of T-cells
which play an important role in maintaining peripheral self
tolerance and preventing immunopathologies [4]. They can
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prevent autoimmunity through the cell surface ligand glu-
cocorticoid-induced tumor necrosis factor receptor (GITR),
cytotoxic T-lymphocyte antigen (CTLA-4) and through the
production of immunosuppressive cytokines. Recently it
has been shown that tumor growth produces generation of
immunosuppressor T-cells [5–8] which, residing at the
tumor site, have been demonstrated to be relevant in pro-
gression of systemic diseases in peripheral blood or lym-
phoid organs [9–11].
The relevance of Treg in the pathogenesis of GBM has
been first suggested by histological studies showing that
Treg infiltrate more high-grade gliomas than low-grade
oligodendrogliomas and brain tissue from non-tumoral
CNS [12, 13]. The fact that the extent of Treg infiltration
correlates with the WHO grade of the tumor, with GBM
showing the largest infiltration, further supports the role for
these cells in GBM [14]. Moreover, in a context of reduced
number of circulating CD4? lymphocytes, an increased
proportion of Treg has been reported in peripheral blood of
patients with malignant glioma [15].
Treg are characterized by CD4?/CD25bright/FOXP3?/
CD127- markers and they are overrepresented at the tumor
site when compared to the circulating ones [4]. However,
the mechanism by which Treg are recruited at the tumor
site is still poorly defined. Although glioblastoma-produced
soluble factors may attract Treg lymphocytes in the tumor
microenvironment, it is not clear whether circulating Treg
in GBM patients behave abnormally or display abnormal
characteristics [4].
CCL2 has been shown to be secreted by a wide variety
of cancer cells in vitro, promoting tumor angiogenesis and
monocyte attraction to the tumor microenvironment. Its
action is mediated by two receptors CCR2 and CCR4 (C–C
chemokine receptor type 2 and 4) [16]. This chemokine is
one of the most important one involved in the recruitment
of blood cells, especially macrophages, into the tissues [17,
18] and a recent work showed that the extravasation of
lymphocytes is mediated by CCL2-expressing astrocytes
[19]. Therefore, we investigated the role of CCL2 secreted
by GBM cell lines in inducing Treg migration toward
tumor microenvironment.
In the present work, we evaluated the effect of glio-
blastoma-released soluble factors on in vitro migration of
purified circulating Treg lymphocytes in a group of GBM
patients and healthy controls. GBM cells were in vitro
exposed to ionizing radiations, routinely used in GBM
treatment, and the effects of this treatment on Treg
migration were also evaluated. Moreover, the expression of
a number of surface markers has been evaluated in order to
compare the circulating Treg phenotype in patients and
controls.
Materials and methods
Patients
Nineteen patients affected by grade IV astrocytoma (GBM,
median age: years, 54; 10 M/9F) followed at our Institution
and 16 healthy individuals (CTR, median age: years, 49;
8 M/8F) were included in the study. Eleven GBM patients
were sampled at first diagnosis and eight at tumor recur-
rence. Blood samples from patients with de novo GBM
were collected before surgery. The patients with recurrent
GBM were included in the study at recurrence, before
surgery and were free from any pharmacological treatment
except for steroids for at least 3 months. Two of first
diagnosis and two of relapsing GBM patients were
receiving steroids (dexamethasone 4–8 mg/day). All the
eight patients with recurrent GBM had been treated with
standard temozolomide therapy according to Stupp’s pro-
tocol (six cycles of adjuvant temozolomide after concom-
itant radio/chemotherapy following first surgery) and
displayed disease recurrence after 3, 3, 4, 5, 5, 6, 7 and
9 months from the last chemotherapy cycle.
This study was approved by the Ethical Committee of
Fondazione IRCCS Istituto Neurologico C. Besta.
Isolation of T regulatory cell population
Peripheral blood mononuclear cells (PBMNC) were iso-
lated from whole blood by density gradient separation
technique following manufacturer’s instructions (Ficoll
PaqueTM Plus, GE Healthcare). Briefly, whole blood was
gently poured in a falcon containing the Ficoll solution at
the bottom and a centrifugation at 600 g for 45 min with no
brake was performed. The central ring of lymphocytes was
isolated from the three separated phases in the tube, gently
collected and washed twice with NaCl 0.9 % solution
(400 g for 10 min and 200 g for 10 min respectively).
PBMNC were resuspended in RPMI medium (3 9 106
cell/mL) and PE-conjugated anti CD4 and Cy5.5-conju-
gated anti CD25 antibodies (Beckman Coulter, cat.
N. A07750 and BioLegend, cat. N. 302608 respectively)
were added for 60 min at 4 C.
Using cytofluorimetric sorting procedure (FACS Van-
tage, Becton–Dickinson), Treg (CD4?/CD25bright) cells
were selected for migration experiments (Fig. 1a). In
addition to Treg, CD4-/CD25- and CD4?/CD25- (non
Treg, NTR, Fig. 1a) were also collected. Purity of Treg
population was assessed by FOXP3 staining (eBioscience,
cat N. 53-47761); purity greater than 90 % was considered
acceptable for migration experiments.
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Fig. 1 a Dot plot showing the typical FSC forward scatter and SSC
side scatter that allowed lymphocytes gating (left). On the right, a
typical flow citometry dot-plot used for isolation of Treg and non-
Treg (NTR1 and NTR2) populations from peripheral blood. Three cell
populations were sorted: a Treg, CD4?CD25bright; b NTR1,
CD4?CD25- and c NTR2, CD4
-CD25-. b Dot-plots showing a
typical result of FOXP3 staining performed on CD4?CD25bright
sorted population: isotypic control staining (left) and anti-FOXP3
staining (right). c Absolute number and percentages of circulating
Treg (CD4?CD25brightFOXP3?) and CD4? lymphocytes in patients
(GBM) and controls (CTR) are reported in the table. No statistically
significant differences could be detected between patients and
controls. Data are expressed both as percentage of circulating
lymphocytes and as absolute number (cells/lL) per microliter of
blood
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Cell culture
Commercially available GBM cell lines U373, U251,
A172, U87 and U138 (American Type Culture Collection,
Manassas, VA) and primary cell culture C210BP, C220CF
[20] were cultured in standard medium (SM), consisting of
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen,
UK) implemented with 10 % FBS and 1 % penicillin–
streptomycin, at 37 C in a humidified atmosphere of 5 %
CO2 in air.
Conditioned media collection
Conditioned media were obtained from culturing human
glioblastoma cell lines in standard medium. After 72 h the
medium was collected, debris eliminated and stored at
-80 C. Two types of media were obtained: (1) condi-
tioned medium (CM), in which GBM cells were cultured in
standard conditions as mentioned above and (2) irradiated
culture medium (irr-CM).
Irradiation culture medium
Cells were seeded 24 h prior treatment at the density of
1.5 9 105 cells in Petri dishes in complete culture medium.
After 24 h medium was substituted with serum free med-
ium and irradiation was performed. Cells were irradiated in
culture dishes at room temperature at a total dose of 8 Gy,
i.e. the maximum tolerated dose delivered in single fraction
in recurrent high-grade glioma patients. Conventional
LINAC irradiation was performed with a 6 MV X-rays
uniform beam produced by a Philips SL 75/5 (Elekta,
Stockholm, Sweden) linear accelerator with a dose/rate of
2 Gy/min for field sizes of 20 9 20 cm2, gantry = 180
and source-to-surface distance was fixed at 100 cm. The
water–solid RW3 were used to assure the 100 % of the
dose in the build-up region on cells.
After treatment, medium was replaced with fresh SM
and cells were cultured for 72 h. Supernatants were then
collected and stored at -80 C.
CM and irr-CM were successively used in Treg migra-
tion assays.
Migration Assay
Purified Treg (CD4?/CD25bright) isolated by FACS sorting
were counted and resuspended in RPMI supplemented with
FBS 10 %. 10,000 purified Treg in 100 lL of medium were
then seeded on each Transwell insert (Costar, 5 lm pore
size) for 24 h. The polycarbonate membrane was previ-
ously coated with 1:3 diluted Matrigel (BD Biosciences)
and positioned in 24 well plates. In each bottom well the
appropriate conditioned medium was added (see above); all
conditions were performed in duplicate. After 24 h, the
Transwell insert was removed, medium from the bottom
well was collected and migrated cells were counted using
Fuchs-Rosenthal counting chambers. Migration is expres-
sed as migration ratio (MR) and represents the fold
increase/decrease compared to the migration measured in
SM, i.e. unconditioned complete medium. Migration of
cells in SM was used as control, to normalize the results
obtained using CM or irr-CM.
In a different set of experiments, the same migration
assay was used to evaluate the effect of CCL2 on migra-
tion; the following media were tested: (a) CCL2 (1 lg/mL)
in SM; (b) CCL2 (1 lg/mL) ? anti CCL2 antibody (Ab-
cam, cat N. ab18677, 0.5 lg/mL in SM); (c) anti CCL2
antibody (0.5 lg/mL) in CM. For all migration experi-
ments, appropriate sets of positive and negative controls
were performed. Migration was also tested toward DMEM
and DMEM ? 10 % FBS as negative controls or
DMEM ? CCL2 (1 lg/mL) and DMEM ? CCL2 (1 lg/
mL) ? anti-CCL2 antibody.
Characterization of peripheral blood Treg
Evaluation of circulating CD4? and Treg was performed.
For the analysis of surface markers, 100 lL of whole blood
(K3EDTA) were triple stained for 20 min at 4 C with PE-
or FITC-conjugated anti-CD4 antibody (Beckman Coulter,
cat. N. A07751/A07750), Pe/Cy5-conjugated anti CD25
antibody (BioLegend, cat. N. 302608) and one of the fol-
lowing antibodies: PE-conjugated anti CCR2 (0.25 lg/
5 9 105 cells, R&D Systems, cat. N. FAB151P), PE-con-
jugated anti CCR4 (0.25 lg/5 9 105 cells, R&D Systems,
cat. N. FAB1567P), FITC-conjugated anti CCR7 (0.5 lg/
5 9 105 cells, eBioscience cat. N. 11-1979-71), PE-con-
jugated anti CD95 (0.5 lg/5 9 105 cells, BD Pharmingen,
cat. N. 555674) and Alexa660-conjugated anti CD127
(0.125 lg/5 9 105 cells, eBioscience, cat. N50-1278-41).
After antibody incubation, erythrocytes were lysed with
BD FACSTM Lysis Solution (Becton–Dickinson, cat.
N. 349202).
For cytoplasmatic markers, a specific Human Regula-
tory Tcell whole blood staining kit (eBioscience, cat. N.
88-8996-40) was utilized with the following antibodies:
PE-conjugated anti CTLA4 (0.5 lg/5 9 105 cells, eBio-
science, cat. N. 12-1529-71), AlexaFluor488-conjugated
anti GITR (0.25 lg/5 9 105 cells, eBioscience, cat.
N. 53-5875-41), FITC-conjugated anti FOXP3 (0.5 lg/
5 9 105 cells, eBioscience, cat N. 53-47761) and FITC-
conjugated anti Helios (0.25 lg/5 9 105 cells, eBio-
science, cat N. 11-9883-80). Appropriate negative controls
were performed for each staining using specific isotype
controls (BD Simultest cat. N. 342409 or BD Tritest cat. N.
342415, Becton–Dickinson).
356 J Neurooncol (2013) 115:353–363
123
Samples were then analyzed by flow cytometry (FACS
Vantage, BD Bioscience) using a specific software (CellQuest
Pro, BD Bioscience). Treg cells were classified as CD4?/
CD25bright/FOXP3? and CD4?/CD25bright/CD127-. CD4?
lymphocytes are expressed by absolute number (cells/lL of
blood) using flow count fluorospheres. Similar to CD4?
lymphocytes, Treg were also expressed as percentage of
CD4? or as absolute number (Treg/lL of blood) calculated, in
double platform, as: CD4?/CD25bright/FOXP3?percent-
age 9 absolute number of CD4? lymphocytes 9 100.
ELISA multiple Array
Following the manufacturer’s instructions, multiple ELISA
array (eBioscience) was performed to measure the con-
centration of the following molecules: angiogenesis factors
(PDGF, HGF, FGF, VEGF), chemokines (EGF, ITAC,
CCL2, SDF1ß), metalloproteases (MMP2 and TIMP2) and
interleukins (IL-1, IL-4, IL-5, IL-8, IL-10-IL 12p70, IL-13,
IFNc-TNFa).
Real time PCR
Total RNA was isolated from Treg sorted from peripheral
blood of three patients and three healthy controls using
RNeasy Mini Kit (Qiagen, Ge). RNA was quantified by
NanoPhotometerTM Pearl (Implen GmbH, Ge) and equal
amounts of all samples were reverse transcribed using
iScript cDNA Synthesis Kit (Bio-Rad Laboratories). Trip-
licate polymerase chain reactions were carried out on an
ABI7500 Real Time PCR Detection System (Applied
Biosystem) using iTaq Universal SYBR Green Supermix
(Bio-Rad Laboratories). Primers sequences for TGF-b1
(forward 50-ACCTGCCACAGATCCCCTAT-30; reverse
50-CTCCCGGCAAAAGGTAGGAG-30) and IL-10 (for-
ward: 50-TACGGCGCTGTCATCGATTT-30; reverse 50-
TAGAGTCGCCACC-CTGATGT-30) were designed using
Primer3 software; mRNAs were amplified and relative
gene expression was evaluated. DCt was evaluated nor-
malising TGF-b1 and IL-10 Ct values to Ct of house-
keeping gene GAPDH (forward 50-GTCGGAGTCAAC
GGATT-30; reverse 50-AAGCTTCCCGTTCTCAG-30).
Data are expressed by a comparative method (2DDCt ),
calculating DDCt as DCtðGBMÞ  DCtðCTRÞ :
Statistical analysis
Unless specified otherwise, the data are presented as
mean ± standard error (SE). Differences in the levels of
investigated parameters between patients (GBM) and
control group (CTR) were analyzed by Student t test or
Spearman’s rank correlation coefficient followed by post
hoc tests, where necessary. p values lower than 0.05 were
considered statistically significant.
Results
CD4? and Treg in GBM patients
Circulating Treg (CD4?/CD25bright/FOXP3?) and CD4?
were analyzed in peripheral blood of GBM patients and
controls and the results are summarized in Fig. 1c.
Although no statistically significant differences could be
observed, the percentage and the absolute number of cir-
culating Treg lymphocytes was higher in GBM patients
compared to controls. On the other hand, the percentage
and the absolute number of CD45?/CD4? lymphocytes
was slightly lower in patients compared to controls
(806 ± 82 and 892 ± 171 cells/lL of blood respectively)
(Fig. 1c).
Migration experiments
Conditioned media
In our experimental conditions, purified Treg of patients
and healthy controls showed a migration ratio respectively
of 3.797 ± 0.545 and 2.879 ± 0.413, indicating that Treg
are much more attracted from CM compared to standard
medium (MR = 1) (Fig. 2a). These differences in migra-
tion were statistically significant for GBM patients
(p = 0.006) and for healthy controls (p = 0.009, Fig. 2a),
but no differences were found between the migration ratio
of patients and healthy controls. To assess if the increased
migration induced by CM was specific for Treg population,
we examined the migration of a non-Treg population
(CD4?/CD25-, Fig 1a). A statistically significant decrease
in migration of NTR population compared to Treg was
observed in both GBM patients and healthy controls
(1.904 ± 0.42 vs 3.157 ± 0.8 and 1.399 ± 0.28 vs
2.055 ± 0.41; p \ 0.05 and p \ 0.043 respectively). As a
matter of fact, the migration ratio of NTR population was
not affected by CM nor in patients or in controls (Fig. 2b).
Role of CCL2
To investigate putative soluble molecules produced in vitro
by GBM cells and involved in the molecular mechanisms
of Treg migration, a panel of 19 soluble factors was
screened by a multiple ELISA array in conditioned media
derived from two human glioblastoma cell lines (A172 and
U87) before and after 8 Gy irradiation. Many of the soluble
factors screened were detectable in the conditioned media
with some differences between glioblastoma cell lines
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(data not shown). Since CCL2 has been described as a key-
factor in Treg migration [21] and was abundantly present in
conditioned media, its concentration was measured by
conventional ELISA in CM and irr-CM (Fig. 3a).
Although not statistically significant, a trend to a cor-
relation between CCL2 concentration in CM and Treg
migration ratio was detected in healthy controls (r2 = 0.42;
p = 0.2, Spearman’s rank correlation coefficient) but not in
GBM patients (Fig. 3c, d). In agreement with this obser-
vation, the addition of an anti-CCL2 antibody to CM to
block CCL2 activity, significantly inhibited Treg migration
in both patients and controls (Fig. 3b). However, in our
experimental conditions, the addition of human recombi-
nant CCL2 (1 lg/mL) to SM did not induce a statistically
significant increase in Treg migration (Fig. 3b).
The effect of irradiation on CCL2 production was not
unambiguous; indeed, irradiation resulted in a statistically
significant increased CCL2 levels in 3 out of the four
cultures tested and in decreased levels in one cell line
(Fig. 3a). However, when these conditioned media (irr-
CM) were used in migration experiments, no correlation
could be observed between variations in Treg migration
ratio and variations in CCL2 concentration (Fig. 4a). As a
matter of fact, overall irr-CM-induced Treg migration
showed a trend to decrease compared to CM in both
patients and controls (Fig. 4b).
Moreover, the surface expression of the CCL2 receptors,
CCR2 and CCR4, has been analyzed in Treg populations.
Both CCL2 receptors were highly expressed in Treg lym-
phocytes with no differences in expression between
patients and controls (Fig. 4c–e).
Treg characterization
Expression of CD127 and HELIOS (Treg-related markers)
and other functional markers has been evaluated in circu-
lating Treg lymphocytes (Fig. 5). Treg population was also
characterized by the screening of surface expression of
molecules involved in autoimmunity, like GITR and
CTLA-4, an apoptosis mediator CD95 and CCR7, an
activator of T and B lymphocytes which can control the
migration of memory T cells to secondary lymphoid
organs. As expected, most of Treg did not express CD127,
while were positive for HELIOS (a marker of naı¨ve Treg)
with no differences between patients and controls (Fig. 5).
CD95 was also highly expressed, while CTLA4, GITR and
CCR7 were expressed in a lower percentage of Treg
without statistically significant differences between
patients and controls, supporting the idea that Treg lym-
phocytes in glioblastoma patients are phenotypically sim-
ilar to that of healthy individuals.
To verify the function of circulating Treg in GBM patients,
we analyzed the production of Treg-specific transcripts such
as IL-10 and TFG-b1 in purified populations. Compared to
healthy controls, GBM patients displayed similar amounts of
transcripts for IL10 (2DDCt = 0.86 ± 0.06). Whereas, TGF-
b1 transcripts were slightly higher in GBM patients compared
to controls (2DDCt = 1.64 ± 0.18), but no statistically sig-
nificant differences were detected.
Discussion
Although the role of various factors involved in the immune
response on clinical evolution of glioma patients is suggested
by a number of studies, the specific role of Treg in GBM
progression requires further investigations [13, 14, 22]. In
fact, while the study by Kim did not show a predictive value
of FOXP3 expression in tumor specimens on progression and
survival in a group of 67 GBM patients [22], the study from
Fig. 2 a Mean migration ratios of Treg in patients (GBM) and
healthy controls (CTR). A statistically significant increase in Treg
migration toward CM was detected both in patients and controls
(student’s t test). Data are expressed as migration ratio, which
represents the fold increase/decrease compared to the migration
measured in unconditioned complete medium (SM). Error bars
represent the standard error. b CM specifically induce migration of
Treg lymphocytes. Migration ratios of purified Treg and NTR was
measured as described above (see also methods). Migration toward
CM was significantly higher in Treg compared to NTR both in GBM
patients (p = 0.05 Student’s t test) and CTR (p = 0.043 Student’s
t test). Data are expressed as mean migration ratio in GBM and CTR
and represent at least two independent experiments run in duplicate.
Standard error is represented by error bars
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Jacobs suggested a moderate increase in survival of GBM
patients displaying less Treg infiltration, compared to
patients with a high proportion of intratumoral Treg [14].
Efforts to improve immunotherapy, supported by the work of
Donson 2012, confirm the importance of the expression of
local immune-related genes on the survival of patients with
high-grade glioma [23].
The data presented here further confirm that in vitro
cultured glioblastoma cells release factors able to attract
Treg lymphocytes. Overall, these results are in agreement
with the long recognized idea that glioblastoma may induce
an immunosuppressive microenvironment which contrib-
utes to the development and the survival of the tumor [24].
In addition, our data indicate that circulating Treg
Fig. 3 a CCL2 concentration (pg/mL) in various CM from glioblas-
toma-derived primary cultures (C210BP and C220CF) and GBM cell
lines (U251, U373 and A172). Cells were either untreated or were
irradiated (C210BP, U251, U138 and A172) by a single dose of 8 Gy.
Data are expressed as mean concentration of at least two different CM
for each cell line or primary culture obtained in independent
experiments. Standard deviations are represented by error bars. *
for these cell lines experiments with irradiated CM were not
performed. b Effect of anti-CCL2 antibodies on Treg migration.
Migration of purified Treg from GBM patients (black histograms) and
healthy controls (gray histograms) has been measured using both
glioblastoma cell lines CM conditioned media and, in parallel, the
same CM added with a blocking anti-CCL2 antibody (0,5 lg/mL)
(CM ? anti-CCL2ab). All data are represented as mean ± standard
error (error bars). c, d Correlation between CCL2 concentration (pg/
mL) and migration ratio is represented for CTR c and GBM patients
d. The mean value (error bars represent standard deviations) of all
migration ratios obtained using each CM (the specific cell line or
primary culture is indicated), were correlated with mean CCL2
concentration measured by ELISA assay in each conditioned medium
(see Fig. 2a). Linear correlation has been evaluated and R2 values are
indicated
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lymphocytes isolated from patients with GBM display
similar characteristics compared to Treg of healthy subject,
further suggesting that the migration of Treg is mainly due
to tumor-released factors rather than to an altered function
of circulating Treg [4, 25].
Indeed, our results showed that the attractant effect
exerted by GBM-conditioned media was greater in Treg
subpopulation than in non-Treg. This was in line with
previously reported data showing that glioblastoma have
relatively few infiltrating lymphocytes, even if T cell
infiltration in GBM has been shown to increase in a WHO-
grade-dependent fashion [26, 27].
However, our data are partially in contrast with data
reported by Crane showing that general T-lymphocytes are
also attracted by CM [4]. Differences in T-lymphocytes
populations may explain this discrepancy since in our
migration test, as non-Treg cells, only CD25- populations
were tested. Although the migration rate was very similar
in both experimental sets, differences in glioma cell lines
used should also be considered.
Significant differences in CCL2 release were detected
among the various glioblastoma cell lines tested (range
10–1,200 ng/mL). However, primary glioblastoma cell
cultures seemed not to behave differently compared to
long-term cultured cell lines, suggesting that both may be
used in this kind of experiments [4].
The mechanisms and molecules that are responsible for
T lymphocytes recruitment at the tumor site are still poorly
known [28]. Investigating some of the molecules that are
relevant as chemoattractant for Treg, we found that CCL2
showed to play a pivotal role. Moreover, the addition of an
anti-CCL2 antibody to the conditioned media almost
completely abrogated the increase of in vitro Treg migra-
tion, indicating that CCL2 has a necessary, but not
Fig. 4 a Effect of irradiation on Treg migration. Conditioned media
were used in Treg migration experiments in patients (GBM) and
controls (CTR). No statistically significant differences were detected
comparing Treg migration induced by CM or irr-CM. Data represent
media of all experiments (error bars represent standard deviations).
b Correlation between irradiation-induced CCL2 release and varia-
tions in Treg MR migration ratio. Irradiation-induced changes in Treg
migration seemed to be independent on irradiation-induced variations
in CCL2 release in the conditioned medium. Histograms represent the
irradiation-induced variation, in the specific cell lines tested, of Treg
migration ratios in GBM patients (empty histograms) or controls (gray
histograms) and CCL2 concentrations in conditioned media (black
histograms). Data refers to a minimum of two independent experi-
ments and are expressed as mean percentage increase/decrease
detected comparing irr-CM with CM. c Expression of CCL2 receptors
in circulating Treg. Percentage of CD4?CD25bright CCR2? and
CD4?CD25bright CCR4? lymphocytes in GBM patients and in
controls. No statistically significant differences were detected. Data
are expressed as mean (error bars represent standard deviations) of all
individuals included in the study. d Expression of CCR2 and CCR4 as
detected by flow cytometry
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exclusive, role in attracting Treg at the tumor site [29, 30].
Similar results have been shown by Crane for CCL2 and
commented by Weller [4, 31].
GBM cell lines and primary cultures seemed to
respond to irradiation increasing CCL2 release in the
conditioned media, similarly to what previously observed
in two meningioma cell lines [32], even if the different
behavior observed in one cell line suggests heterogeneity
in the response. However, in our experimental
conditions, this increase did not result in a rise of Treg
migration, nor in patients or in controls, and no statis-
tically significant differences in CCL2 receptors were
detected, suggesting a ‘‘normal’’ phenotype of circulating
Treg in GBM patients. Taken together our data suggest
that, although CCL2 plays a crucial role in the first
phases of Treg attraction, a synergy of protein interac-
tions is likely needed to drive effective migration to the
tumor site in GBM [4, 33].
Fig. 5 a–f Treg markers expression in FOXP3?CD4?CD25? circulat-
ing lymphocytes as detected by flow cytometry. FOXP3?CD4?CD25?
were first gated and the expression of each marker was calculated:
a CD127; b Helios; c CCR7; d CD95; e GITR; f CTLA4. g Histogram that
represent the percentage of Treg specific markers CD127 and Helios and
h proteins involved in activation (CCR7), apoptosis (CD95) and in
autoimmunity (GITR and CTLA4). Data are expressed as mean ± SD of
percentages detected in patients and controls
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Data regarding phenotypic and functional analysis of
circulating Treg further suggest that this immunosuppres-
sive subpopulation display similar characteristics in GBM
patients and in healthy controls [4]. Among the molecules
studied, GITR upregulation in GBM-infiltrating lympho-
cytes has been reported to be particularly pronounced on
infiltrating Treg [34]. In our patients, expression of GITR
on circulating Treg was almost doubled compared to
healthy controls; however, due to the high variability
observed in patients, this increase was not statistically
significant. Since GITR-targeted immunotherapy has been
shown to positively impact tumor immunity, this pre-
liminary observation may deserve further attention [35,
36]. The role of other Treg-associated molecules such as
ICOS (inducible costimulatory molecules) in immune
escape of glioma, remains to be elucidated [37].
A further and deeper knowledge of the complex inter-
actions between systemic immunity, locoregional immu-
nosuppressive and chemoattractant factors and tumor-
versus therapy-induced alterations is mandatory for the
development of effective immunotherapeutic protocols in
glioblastoma, in which the standard of cure contemplates
immunosuppressive therapy.
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